The short version of dihexa fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
Sidestream smoke is smoke which goes into the air directly from a burning cigarette, cigar, or smoking pipe. Sidestream smoke is the main component (around 85%) of second-hand smoke (SHS), also known as Environmental Tobacco Smoke (ETS) or passive smoking. The relative quantity of chemical constituents of sidestream smoke are different from those of directly inhaled ("mainstream") smoke, although their chemical composition is similar. Sidestream smoke has been classified as a Class A carcinogen by the U.S. Environmental Protection Agency.
=== Nuclear activism === The aftermath of the Manhattan Project and his wife Ava's pacifism changed Pauling's life profoundly, and he became a peace activist. In June 1945, a "May-Johnson Bill" began that would become the Atomic Energy Act of 1946 (signed August 1, 1946). In November 1945, Pauling spoke to the Independent Citizens Committee of the Arts, Sciences and Professions (ICCASP) on atomic weapons; shortly after, wife Ava and he accepted membership. On January 21, 1946, the group met to discuss academic freedom, during which Pauling said, "There is, of course, always a threat to academic freedom – as there is to the other aspects of the freedom and rights of the individual, in the continued attacks which are made on this freedom, these rights, by the selfish, the overly ambitious, the misguided, the unscrupulous, who seek to oppress the great body of mankind in order that they themselves may profit – and we must always be on the alert against this threat, and must fight it with vigor when it becomes dangerous." In 1946, he joined the Emergency Committee of Atomic Scientists, chaired by Albert Einstein. Its mission was to warn the public of the dangers associated with the development of nuclear weapons.
A script version of the words Dunkin' Donuts was filed on March 31, 1955, and registered on February 2, 1960. A later logo was for a drawing and word logo depicting a figure with a doughnut for a head and a coffee cup and doughnut body wearing a garrison cap, with Dunkin' emblazoned on both the coffee cup and cap. The design was rendered primarily in yellow and brown. The logo was applied for on June 23, 1958, registered on May 23, 1961, and put into use on July 1, 1964. In 1966, the company began using a hot pink color for its branding and used a logo showing a stylized coffee cup with the company's name rendered on one line as a circle, evoking a doughnut dunking into the cup. In 1980, bright orange was added to the hot pink. As of 2014, the logo was a variation of the logo that has been in use since 1980: an all-capitals rendering of the words Dunkin' Donuts (Dunkin' in orange, Donuts in pink) in a thick, Frankfurter typeface with a coffee cup outlined in brown with a "DD" monogram. In September 2018, the company announced that it would shorten its name to Dunkin', with a wider roll out beginning in January 2019. The company acknowledged "Dunkin'" was already a common name for the chain among customers and in its marketing (including the slogan "America Runs on Dunkin'"), and that the rebranding would reflect the chain's continuing shift towards being a "beverage-led" brand at a time when consumers have shown a preference for healthier trends and options as they eat fewer doughnuts. While stores in the U.S.
Elena Molokhovets's classic Russian cookbook A Gift to Young Housewives gives the first known recipe for Govjadina po-strogonovski, s gorchitseju, "Beef à la Stroganov, with mustard", in its 1871 edition. The recipe involves beef cubes (not strips) prepared in a dry marinade of salt and allspice, and then sautéed in butter. The sauce is a simple roux mixed with prepared mustard and broth, and finished with a small amount of sour cream: no onions, no mushrooms and no alcohol. In 1891, the French chef Charles Brière, who was working in Saint Petersburg, submitted a recipe for beef Stroganoff to a competition sponsored by the French magazine L'Art culinaire. This led Larousse Gastronomique to assume that he was the inventor of this dish, but both the recipe and the name existed before then.
Sources: en.wikipedia.org
== U.S. Patents == Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 9,034,610. Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 8,435,765. Polypeptides and biosynthetic pathways for the production of monatin and its precursors, U.S. Patent 8,372,989. Production of monatin and monatin precursors, U.S. Patent 8,206,955. Polypeptides and biosynthetic pathways for the production of monatin and its precursors. U.S. Patent 7,572,607. Production of 3-hydroxypropionic acid in recombinant organisms, U.S. Patent 6,852,517. Microbial production of 1,2-propanediol from sugar, U.S. Patent 6,303,352. Microbial production of 1,2-propanediol from sugar, U.S. Patent 6,087,140. Novel glycerol phosphatase with stereo-specific activity. U.S. Patent 5,733,749. Polysaccharide composition and process for preparing same. U.S. Patent 5,288,618. Galactomannan polysaccharide producing organism. U.S. Patent 5,130,249.
=== Terpolymers === Terpolymers of PVDF are the most promising one in terms of electromechanically induced strain. The most commonly used PVDF-based terpolymers are P(VDF-TrFE-CTFE) and P(VDF-TrFE-CFE). This relaxor-based ferroelectric terpolymer is produced by random incorporation of the bulky third monomer (chlorotrifluoroethylene, CTFE) into the polymer chain of P(VDF-TrFE) copolymer (which is ferroelectric in nature). This random incorporation of CTFE in P(VDF-TrFE) copolymer disrupts the long-range ordering of the ferroelectric polar phase, resulting in the formation of nano-polar domains. When an electric field is applied, the disordered nano-polar domains change their conformation to all-trans conformation, which leads to large electrostrictive strain and a high room-temperature dielectric constant of ~50.
Flying Officer (now Acting Wing Commander) Robert Charles Timothy, Royal Air Force, 30389992. Civil Enass Abo Hamed. Co-Founder and Chief Executive Officer, H2GO Power. For services to Engineering and to Enterprise. Dr. Helen Mary Abrahams (Helen Pain). Chief Executive, Royal Society of Chemistry and lately Chair, Board of Trustees, Science Council. For services to Science. Sheila Ann Abrahams. Founder, Freelance Hairdressers' Association. For services to the Hairdressing Industry. Gerald Ronald Joseph Adams. For voluntary services to the community in Barry, Glamorgan. Bayo Adelaja. Founder and Chief Executive Officer, Do It Now Now. For services to Social Mobility, to Financial Inclusion and to Entrepreneurship. Dr. Olurotimi Babatunde Adesanya. Founder and Chair, African and Caribbean Dental Association UK and Principal Dentist, Watling Street Dental Care. For services to Oral Health. Taslima Parveen Ahmad. Founder, Creative Design and Manufacture UK. For services to Disadvantaged People and to the Minority Ethnic Community. Shabnam Ahmed Butt. Lead for Adult Safeguarding, Camden London Borough Council. For services to Social Care. Jill Alcock (Jill Clewes). Founder, Jill Clewes Academy for Theatre Arts. For services to the Arts and to Charity. Michael Allen. Principal, Lisneal College. For services to Education. Ethel Gloria Anderson. For services to the community in St Ann's, Nottingham. Samuel James Anderson. Founder and Chief Executive, IceMOS Technology. For services to Economic Development in Northern Ireland. Colin Trevor Whitney Angel.
Clinical pathologists may assist physicians in interpreting complex tests such as platelet aggregometry, hemoglobin or serum protein electrophoresis, or coagulation profiles. If interfering substances are suspected, they may recommend alternate test methods. For example, hemolysis, icterus, lipemia, or heterophile antibodies may confound results obtained by traditional methods such as ion-selective electrodes, enzymatic assays or immunoassays. Alternate methods such as blood gas analysers, point-of-care testing or mass spectrometry may help resolve the clinical question.
=== Elongation stages === Loading: Analogous to the starting stage, each module loads its specific amino acid onto its PCP-domain. Condensation: The C-domain catalyzes the amide bond formation between the thioester group of the growing peptide chain from the previous module with the amino group of the current module. The extended peptide is now attached to the current PCP-domain. Condensation-Cyclization: Sometimes the C-domain is replaced by a Cy-domain, which, in addition to the amide bond formation, catalyzes the reaction of the serine, threonine, or cysteine sidechain with the amide-N, thereby forming oxazolidines and thiazolidine, respectively. Epimerization: Sometimes an E-domain epimerizes the innermost amino acid of the peptide chain into the D-configuration. This cycle is repeated for each elongation module.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.